RenovoRx, Inc. (RNXT)
RenovoRx, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mountain View, CA, US. The stock last traded at $1.14, down 0.98% on the session, giving a market capitalisation of $51.3M. On trailing twelve-month figures it carries a trailing P/E of -3.39, a net margin of -824.0%. Its beta of 0.99 implies it has historically moved less than the broad market.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RenovoRx, Inc. is most often compared with the following Healthcare names: